Brief: Theriva Biologics Announces Orphan Drug Designation Granted By The U.S. FDA For Vcn-01 For The Treatment Of Pancreatic Cancer
27/06/2023 22:48
Theriva Biologics Inc TOVX.A :
* THERIVA BIOLOGICS ANNOUNCES ORPHAN DRUG DESIGNATION
GRANTED BY
THE U.S. FDA FOR VCN-01 FOR THE TREATMENT OF PANCREATIC CANCER
Source text for Eikon: ID:nGNEbG9bVG
Further company coverage: TOVX.A
Recent news on Theriva Biologics
See all newsTheriva Biologics Q2 net loss narrows on lower R&D costs, expenses
Brief: Theriva™ Biologics Announces Upcoming Presentation Of Additional Data From The Virage Phase 2B Clinical Trial Of Vcn-01 In Metastatic Pancreatic Cancer At Aacr 2026 Annual Meeting
Brief: Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications
Brief: Theriva Biologics Implements 32% Workforce Reduction - SEC Filing
Brief: Theriva™ Biologics Announces Presentation Of Data From Vcn-01 Retinoblastoma Phase 1 Clinical Trial At Asco 2025